Adagene
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building C14 Xinghu Street Suzhou Indust...Phone Number
+86 51287773632Website
www.adagene.comRevenue
<$5 MillionStock Symbol
ADAGIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Adagene
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.Explore more
Adagene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adagene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Adagene has new funding data
Click to see if Adagene had a recent Job posting/layoffs
Product Launch: Get notified when Adagene launches new products
Earning: See what the market has to say on Adagene recently announced quarterly report
Adagene, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Adagene has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Adagene is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Adagene
Recommended Actions
Reach out to Masked Content who joined Adagene as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Adagene is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Adagene is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Adagene.
Adagene financials insights
Gather financial insights about Adagene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$8M
2016
Series B
$28M
2018
Series C
$50M
2020
Series D
$69M
2021
Stock Offering
$140M
2025
Other Financing Round
$25M
Adagene Tech Stack
A closer look at the technologies used by Adagene
See more technologies
Most Recent Scoops
Open Position
Open Position
Project
Adagene has stated publicly that enrollment for the randomized phase II trial should be completed before the end of this year.
Pharmaceuticals, Clinical Operations
Project
Adagene has announced that its ADG126 binds to a different epitope compared to ipilimumab, tremelimumab, or botensilimab, resulting in better Fc orientation and immune synapse formation. Adagene believes ADG126's ADCC is at least 10 times higher versus ipilimumab.
Product Development, Bioengineering, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Adagene News & Media
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NAdagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study […]Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patientsAdagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board (SAB).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adagene
Sign Up For FreeTo access detailed company insights
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.... Read More
